The nitric oxide (No) donor sodium nitroprusside (snp) and its potential for the schizophrenia therapy: Lights and shadows

Abstract

Schizophrenia is a severe psychiatric disorder affecting up to 1% of the worldwide popula-tion. Available therapy presents different limits comprising lack of efficiency in attenuating negative symptoms and cognitive deficits, typical features of schizophrenia and severe side effects. There is pressing requirement, therefore, to develop novel neuroleptics with higher efficacy and safety. Nitric oxide (NO), an intra‐ and inter‐cellular messenger in the brain, appears to be implicated in the patho-genesis of schizophrenia. In particular, underproduction of this gaseous molecule is associated to this mental disease. The latter suggests that increment of nitrergic activity might be of utility for the medi-cation of schizophrenia. Based on the above, molecules able to enhance NO production, as are NO donors, might represent a class of compounds candidates. Sodium nitroprusside (SNP) is a NO donor and is proposed as a promising novel compound for the treatment of schizophrenia. In the present review, we intended to critically assess advances in research of SNP for the therapy of schizophrenia and discuss its potential superiority over currently used neuroleptics. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.